{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:38:40Z","timestamp":1771364320136,"version":"3.50.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ccl.2019.07.011","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T16:08:58Z","timestamp":1570118938000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Arrhythmogenic Anticancer Drugs in Cardio-Oncology"],"prefix":"10.1016","volume":"37","author":[{"given":"Isaac","family":"Rhea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Hernandez","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ccl.2019.07.011_bib1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","article-title":"Anticipating the \"silver tsunami\": prevalence trajectories and comorbidity burden among older cancer survivors in the United States","volume":"25","author":"Bluethmann","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","article-title":"Cardiovascular disease mortality among breast cancer survivors","volume":"27","author":"Bradshaw","year":"2016","journal-title":"Epidemiology"},{"issue":"20","key":"10.1016\/j.ccl.2019.07.011_bib3","doi-asserted-by":"crossref","first-page":"e010101","DOI":"10.1161\/JAHA.118.010101","article-title":"Incidence of cancer treatment-induced arrhythmia associated with novel targeted chemotherapeutic agents","volume":"7","author":"Nickel","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.011_bib4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11739-011-0701-9","article-title":"Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study","volume":"7","author":"Erichsen","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.ccl.2019.07.011_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11739-008-0124-4","article-title":"First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation","volume":"3","author":"Guzzetti","year":"2008","journal-title":"Intern Emerg Med"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib7","first-page":"340","article-title":"Developing a comprehensive cardio-oncology program at a Cancer Institute: the Moffitt Cancer Center experience","volume":"11","author":"Fradley","year":"2017","journal-title":"Oncol Rev"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Hu","year":"2013","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/SLA.0000000000000960","article-title":"New-onset atrial fibrillation post-surgery for esophageal and junctional cancer: incidence, management, and impact on short- and long-term outcomes","volume":"260","author":"Mc Cormack","year":"2014","journal-title":"Ann Surg"},{"issue":"22","key":"10.1016\/j.ccl.2019.07.011_bib10","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2019.07.011_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.smj.0000257382.89910.fe","article-title":"Early and late arrhythmogenic effects of doxorubicin","volume":"100","author":"Kilickap","year":"2007","journal-title":"South Med J"},{"issue":"9","key":"10.1016\/j.ccl.2019.07.011_bib12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.amjcard.2016.07.049","article-title":"Prognostic significance of new-onset atrial fibrillation in patients with non-Hodgkin's lymphoma treated with anthracyclines","volume":"118","author":"Amioka","year":"2016","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","article-title":"Cancer chemotherapy and cardiac arrhythmias: a review","volume":"38","author":"Tamargo","year":"2015","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacep.2016.08.009","article-title":"Burden of cardiac arrhythmias in patients with anthracycline-related cardiomyopathy","volume":"3","author":"Mazur","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib15","doi-asserted-by":"crossref","first-page":"e000701","DOI":"10.1136\/openhrt-2017-000701","article-title":"Rates and risk\u00a0of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies","volume":"4","author":"Fradley","year":"2017","journal-title":"Open Heart"},{"issue":"9","key":"10.1016\/j.ccl.2019.07.011_bib16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/bmt.2017.148","article-title":"The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution","volume":"52","author":"Arun","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","article-title":"Melphalan-induced supraventricular tachycardia: incidence and risk factors","volume":"34","author":"Feliz","year":"2011","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1753944712464102","article-title":"Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors","volume":"6","author":"Sureddi","year":"2012","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"9","key":"10.1016\/j.ccl.2019.07.011_bib19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2015.127","article-title":"Arrhythmias in the setting of hematopoietic cell transplants","volume":"50","author":"Tonorezos","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ccl.2019.07.011_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijcard.2015.10.083","article-title":"Burden of arrhythmias in patients with multiple myeloma","volume":"203","author":"Shah","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40292-018-0256-1","article-title":"Evaluation of cardiovascular toxicity associated with treatments containing proteasome inhibitors in multiple myeloma therapy","volume":"25","author":"Iannaccone","year":"2018","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib22","article-title":"Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma","volume":"3","author":"Chen","year":"2017","journal-title":"Cardio Oncol"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.011_bib23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ccl.2019.07.011_bib24","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J"},{"issue":"15","key":"10.1016\/j.ccl.2019.07.011_bib25","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ccl.2019.07.011_bib26","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/annonc\/mdm489","article-title":"Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma","volume":"18","author":"Mego","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ccl.2019.07.011_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00280-011-1753-2","article-title":"Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma","volume":"69","author":"Petrini","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ccl.2019.07.011_bib29","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12185-018-2401-y","article-title":"Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial)","volume":"107","author":"Ishikawa","year":"2018","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccep.2015.03.013","article-title":"QT prolongation and oncology drug development","volume":"7","author":"Fradley","year":"2015","journal-title":"Card Electrophysiol Clin"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.ccl.2019.07.011_bib35","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","article-title":"Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials","volume":"17","author":"Yun","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.ccl.2019.07.011_bib37","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"issue":"25","key":"10.1016\/j.ccl.2019.07.011_bib38","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ccl.2019.07.011_bib40","series-title":"Imbruvica (ibrutinib) [package insert]","year":"2018"},{"key":"10.1016\/j.ccl.2019.07.011_bib41","series-title":"Imbruvica: EPAR- product information [package insert]","year":"2018"},{"issue":"25","key":"10.1016\/j.ccl.2019.07.011_bib42","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.ccl.2019.07.011_bib43","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ccl.2019.07.011_bib44","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A\u00a0comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ccl.2019.07.011_bib45","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2019.07.011_bib46","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer","volume":"25","author":"D'Souza","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"20","key":"10.1016\/j.ccl.2019.07.011_bib48","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ccl.2019.07.011_bib51","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"issue":"16","key":"10.1016\/j.ccl.2019.07.011_bib52","doi-asserted-by":"crossref","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-019-0797-z","article-title":"Anticoagulation of cardiovascular conditions in the cancer patient: review of old and new therapies","volume":"21","author":"Rhea","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.ccl.2019.07.011_bib54","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"10.1016\/j.ccl.2019.07.011_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FJC.0000000000000607","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and thrombocytopenia","volume":"72","author":"Janion-Sadowska","year":"2018","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"38","key":"10.1016\/j.ccl.2019.07.011_bib56","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.ccl.2019.07.011_bib57","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/CIRCULATIONAHA.106.638395","article-title":"Results\u00a0from the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter","volume":"114","author":"Da Costa","year":"2006","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.011_bib58","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"issue":"13","key":"10.1016\/j.ccl.2019.07.011_bib59","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jacc.2015.06.028","article-title":"2015 ACC\/HRS\/SCAI left atrial appendage occlusion device societal overview","volume":"66","author":"Masoudi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jacep.2016.03.001","article-title":"Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter-defibrillators","volume":"3","author":"Enriquez","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ahj.2009.10.019","article-title":"Etiology of sudden death in the community: results of anatomical, metabolic, and genetic evaluation","volume":"159","author":"Adabag","year":"2010","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib62","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.mayocp.2015.02.011","article-title":"Rare incidence of ventricular tachycardia and torsades de Pointes in hospitalized patients with prolonged QT who later received levofloxacin: a retrospective study","volume":"90","author":"Stancampiano","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.011_bib63","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncologist"},{"issue":"Suppl 11","key":"10.1016\/j.ccl.2019.07.011_bib64","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/cncr.28061","article-title":"Cardiac toxicity in cancer survivors","volume":"119","author":"Lenihan","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.011_bib65","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14740338.2017.1354987","article-title":"Cancer drugs and QT prolongation: weighing risk against benefit","volume":"16","author":"Menna","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-018-0691-0","article-title":"Electrophysiologic toxicity of chemoradiation","volume":"20","author":"Armanious","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib67","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1742-1241.2007.01323.x","article-title":"5-Fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring","volume":"61","author":"Yilmaz","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib68","first-page":"430","article-title":"A\u00a0retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center","volume":"62","author":"Khan","year":"2012","journal-title":"J\u00a0Pak Med Assoc"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib69","first-page":"58","article-title":"5-Fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer","volume":"18","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib70","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1078155214563814","article-title":"Capecitabine-induced ventricular fibrillation arrest: possible Kounis syndrome","volume":"22","author":"Kido","year":"2016","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"14_suppl","key":"10.1016\/j.ccl.2019.07.011_bib71","doi-asserted-by":"crossref","first-page":"8107","DOI":"10.1200\/jco.2004.22.90140.8107","article-title":"Cardiac toxicity of 5FU: does prophylactic telemetry monitoring of patients at increased risk for cardiac toxicity improve safety? A 10-year experience","volume":"22","author":"Pizzolato","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ccl.2019.07.011_bib72","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.ccl.2019.07.011_bib73","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/CAD.0b013e328012d023","article-title":"QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines","volume":"18","author":"Arbel","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/mol.66.1.33","article-title":"Mechanisms of arsenic-induced prolongation of cardiac repolarization","volume":"66","author":"Ficker","year":"2004","journal-title":"Mol Pharmacol"},{"issue":"19","key":"10.1016\/j.ccl.2019.07.011_bib75","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","article-title":"Effect of arsenic trioxide on QT interval in patients with advanced malignancies","volume":"21","author":"Barbey","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib76","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.V98.2.266","article-title":"Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide","volume":"98","author":"Westervelt","year":"2001","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.ccl.2019.07.011_bib77","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","article-title":"Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide","volume":"32","author":"Roboz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","article-title":"Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase","volume":"2","author":"Kerkela","year":"2009","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib81","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11886-016-0730-0","article-title":"Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation","volume":"18","author":"Viganego","year":"2016","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.011_bib82","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3904\/kjim.2014.29.1.23","article-title":"Risks associated with sunitinib use and monitoring to improve patient outcomes","volume":"29","author":"Choi","year":"2014","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.ccl.2019.07.011_bib83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc Health Risk Manag"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.011_bib84","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.ccl.2019.07.011_bib85","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1038\/srep08629","article-title":"The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells","volume":"5","author":"Zhou","year":"2015","journal-title":"Sci Rep"},{"issue":"34","key":"10.1016\/j.ccl.2019.07.011_bib86","doi-asserted-by":"crossref","first-page":"35589","DOI":"10.18632\/oncotarget.5853","article-title":"What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment","volume":"6","author":"Bronte","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ccl.2019.07.011_bib87","series-title":"Zelboraf (vemurafenib) [package insert]","year":"2011"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.011_bib88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.011_bib89","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib90","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ccl.2019.07.011_bib91","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.011_bib92","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00280-017-3471-x","article-title":"Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study","volume":"80","author":"de Jong","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18","key":"10.1016\/j.ccl.2019.07.011_bib93","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ccl.2019.07.011_bib94","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.011_bib95","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0002-9149(86)80029-7","article-title":"Unexplained sinus bradycardia: clinical significance and long-term prognosis in apparently healthy persons older than 40 years","volume":"58","author":"Tresch","year":"1986","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.ccl.2019.07.011_bib96","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-14-3157","article-title":"FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"21","author":"Khozin","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ccl.2019.07.011_bib97","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.622","article-title":"Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)","volume":"5","author":"Ou","year":"2016","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.ccl.2019.07.011_bib98","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/JTO.0b013e3182307e06","article-title":"Asymptomatic profound sinus bradycardia (heart rate <\/=45) in non-small cell lung cancer patients treated with crizotinib","volume":"6","author":"Ou","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"issue":"7","key":"10.1016\/j.ccl.2019.07.011_bib99","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14737140.2015.1045493","article-title":"When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs","volume":"15","author":"Gallucci","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"10.1016\/j.ccl.2019.07.011_bib100","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.28040","article-title":"Heart rate decrease during crizotinib treatment and potential correlation to clinical response","volume":"119","author":"Ou","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ccl.2019.07.011_bib101","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","article-title":"Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms","volume":"111","author":"McGuire","year":"1989","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.ccl.2019.07.011_bib102","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","article-title":"Cardiac disturbances during the administration of taxol","volume":"9","author":"Rowinsky","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.011_bib103","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.ccl.2019.07.011_bib104","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2019.07.011_bib105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"issue":"18","key":"10.1016\/j.ccl.2019.07.011_bib106","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.ccl.2019.07.011_bib107","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865119300608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865119300608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:52:11Z","timestamp":1760007131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865119300608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0733865119300608"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2019.07.011","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arrhythmogenic Anticancer Drugs in Cardio-Oncology","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2019.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}